Gotistobart Response Rate Bests Chemo in Pretreated NSCLC

Published Date: 07 Apr 2026

Previously treated patients with NSCLC respond to anti-CTLA-4 therapy.

Read Full News

Latest News

Oncology Care Model’s Net Losses Well Exceed Savings

But the CMS’s cancer-focused alternative payment model’s losses “mask successes” that should serve as lessons, experts say.

MRD-Guided Azacitidine May Delay Relapse in AML, MDS

New data highlight the activity and safety of MRD-guided preemptive azacitidine in patients with myelodysplastic neoplasms or AML who develop MRD positivity.

HER3 Antibody Drug Conjugate Shows Promise in NSCLC

Researchers examine overall response rates of a HER3-targeting antibody-drug conjugate in pretreated patients with non-small cell lung cancer.

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

A dose-dense modified Stanford V regimen may improve early complete responses and allow some pediatric patients with low-risk Hodgkin lymphoma to skip radiotherapy.

Older Age Alone Does Not Limit Adagrasib Benefit in NSCLC

In a small phase II study of patients with KRAS G12C-mutated NSCLC, poor performance status, not advanced age, was associated with reduced treatment response.

Morning Immunotherapy Does Not Boost Lung Cancer Survival

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung cancer begs to differ.

Todays Updates

Swiss Industry Body Says US Tariffs on Pharmaceuticals Will Harm Patients

U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, ⁠supply chains and ultimately will harm patients, Switzerland's...

China Tightens Border Controls, Culls Cattle Amid Foot-and-mouth Outbreak

(Refiles to adjust the dateline)

Beyond P Values: Defining True Clinical Effect Size

In the latest Skills Lab, Dr Bishal Gyawali breaks down effect size in oncology, revealing how overpowered trials can turn trivial gains into 'significant' results.

For Angina Relief With CTO PCI, Choose Your Patients Wisely

John Mandrola discusses the sham-controlled trial of percutaneous coronary intervention for chronic total occlusions with ORBITA-CTO investigators Sarosh Khan and John Davies.

Neurologists Alone Can’t Meet the Demand for Brain Health

Neurologists Kathrin LaFaver and Lidia Moura discuss successful strategies to combat the shortage of neurologists and the increasing need for clinicians to tackle brain health.

Conference MDAngle: AAN 2026 Relapsing-Remitting Multiple Sclerosis

Insights from AAN 2026, including anticipated presentations, key takeaways, and how emerging research in RRMS may affect patient care.

Rethinking GP Training to Meet Australia’s Rising Demand

To confront its GP shortage, Australia is expanding rural training, funding, and new medical school models to rebuild its primary care workforce.

Todays Updates

Swiss Industry Body Says US Tariffs on Pharmaceuticals Will Harm Patients

U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, ⁠supply chains and ultimately will harm patients, Switzerland's...

China Tightens Border Controls, Culls Cattle Amid Foot-and-mouth Outbreak

(Refiles to adjust the dateline)

Beyond P Values: Defining True Clinical Effect Size

In the latest Skills Lab, Dr Bishal Gyawali breaks down effect size in oncology, revealing how overpowered trials can turn trivial gains into 'significant' results.

For Angina Relief With CTO PCI, Choose Your Patients Wisely

John Mandrola discusses the sham-controlled trial of percutaneous coronary intervention for chronic total occlusions with ORBITA-CTO investigators Sarosh Khan and John Davies.

Neurologists Alone Can’t Meet the Demand for Brain Health

Neurologists Kathrin LaFaver and Lidia Moura discuss successful strategies to combat the shortage of neurologists and the increasing need for clinicians to tackle brain health.

Conference MDAngle: AAN 2026 Relapsing-Remitting Multiple Sclerosis

Insights from AAN 2026, including anticipated presentations, key takeaways, and how emerging research in RRMS may affect patient care.

Rethinking GP Training to Meet Australia’s Rising Demand

To confront its GP shortage, Australia is expanding rural training, funding, and new medical school models to rebuild its primary care workforce.

Latest News

But the CMS’s cancer-focused alternative payment model’s losses “mask successes” that should serve as lessons, experts say.

New data highlight the activity and safety of MRD-guided preemptive azacitidine in patients with myelodysplastic neoplasms or AML who develop MRD positivity.

Researchers examine overall response rates of a HER3-targeting antibody-drug conjugate in pretreated patients with non-small cell lung cancer.

A dose-dense modified Stanford V regimen may improve early complete responses and allow some pediatric patients with low-risk Hodgkin lymphoma to skip radiotherapy.

In a small phase II study of patients with KRAS G12C-mutated NSCLC, poor performance status, not advanced age, was associated with reduced treatment response.

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung cancer begs to differ.

News All Time

From Pathology to Precision: The Story of Leukemia Therapy

From 19th century ‘white blood’ observations and pathological anatomy to the discovery of BCR-ABL and imatinib, leukemia care evolved from near-certain death to precise, life-extending therapies.

Canadian Group Calls for Earlier Colorectal Cancer Screening

Modelling shows fewer cases and deaths with screening starting at age 45 years.

Q&A: Nipple-Sparing Mastectomy After Breast Radiation

Although many surgeons avoid it, nipple-sparing mastectomy after radiation is a feasible alternative to skin-sparing mastectomy and may help preserve patients’ psychological well-being.

Triplet Therapy Improves Posttransplant Outcomes in Myeloma

A phase 3 trial examines whether carfilzomib-lenalidomide-dexamethasone maintenance therapy improves disease control compared with lenalidomide alone in patients with multiple myeloma.

FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma

The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

In a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

Older Adults With Advanced Cancer Prioritize Quality of Life

Most older adults with advanced cancer value quality of life over extending survival, but that preference may not translate to clinical care or outcomes.

MRI-Guided TULSA Speeds Recovery vs Robotic Prostatectomy

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or immunotherapeutic payload to cancer cells.

Shorter but More Intense RT: A Better Option for HNSCC?

A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in patients with locally advanced HNSCC receiving concurrent chemotherapy.

Adjuvant Tx May Boost Survival in Bilateral Breast Cancer

A population-based cohort study finds that an increased use of adjuvant systemic therapy can improve survival in patients with metachronous and synchronous bilateral breast cancer.

Chemoimmunotherapy Boosts Head and Neck Cancer Response

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Have the Harms of Lung Cancer Screening Been Exaggerated?

Three medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

Despite FDA package insert recommendations, most patients with breast cancer who are prescribed CDK4/6 inhibitors do not receive liver function tests before starting treatment.

Alternative Medicine for Breast Cancer: Study Raises Concern

Patients who receive both standard medical treatment and complementary and alternative therapies have higher mortality — possibly due to reduced use of endocrine therapy and radiation.

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

MiR-371 isn’t ready for the clinic yet, but it is ready for interventional trials to see if it can refine adjuvant chemotherapy decisions in stage I testicular cancer.

Recommended News For You

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor

Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma

No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma

'It's rare and it's scary.' Dark spot on your fingernail could mean cancer

Black women have a higher risk of dying from all types of breast cancer, meta-analysis reveals

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study

Recommended Articles For You

Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025 

Understanding the Importance of Knowing Your MCV Normal Range 

Discovering the Benefits of TNK: A Comprehensive Blog Article  

Liquid Biopsy in SCLC: cfDNA Profiling for Diagnosis and Treatment Monitoring 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

MRD-Guided Azacitidine May Delay Relapse in AML, MDS

2.

According to JAMA, women who have false-positive mammogram results are at a higher risk of developing breast cancer over time.

3.

COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment

4.

It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.

5.

Both men and women who receive the HPV vaccine have a lower risk of developing multiple cancer types.

1.

Cracking Oncology Drug Resistance: New Strategies to Overcome Challenges in Modern Cancer Therapy

2.

Case Study: Genomic Medicine in Precision Oncology

3.

Understanding Mean Corpuscular Volume: A Comprehensive Guide 

4.

Cardio-Oncology: Managing Heart Failure in Survivors of Cancer

5.

Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

2.

Navigating the Complexities of Ph Negative ALL - Part XVI

3.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV

5.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot